Equillium (NASDAQ:EQ) COO Sells $42,731.12 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 14,584 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $2.93, for a total transaction of $42,731.12. Following the completion of the transaction, the chief operating officer owned 62,586 shares of the company’s stock, valued at approximately $183,376.98. The trade was a 18.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The stock was sold at an average price of $2.80, for a total transaction of $240,833.60.
• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total transaction of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total transaction of $362,438.00.

Equillium Price Performance

Shares of NASDAQ:EQ opened at $2.94 on Monday. The stock has a market cap of $185.90 million, a P/E ratio of -9.19 and a beta of 1.77. The firm has a fifty day moving average price of $2.20 and a 200 day moving average price of $1.71. Equillium, Inc. has a 1-year low of $0.27 and a 1-year high of $3.45.

Equillium (NASDAQ:EQ) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Sell-side analysts expect that Equillium, Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of Equillium

Several hedge funds have recently made changes to their positions in EQ. Aberdeen Group plc acquired a new stake in shares of Equillium in the 3rd quarter worth $543,000. Vanguard Group Inc. lifted its stake in shares of Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock worth $1,879,000 after acquiring an additional 489,855 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Equillium in the 3rd quarter worth $99,000. Two Sigma Investments LP acquired a new stake in shares of Equillium in the 3rd quarter worth $190,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Equillium in the 3rd quarter worth $7,951,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Raymond James Financial reiterated a “strong-buy” rating and set a $7.00 price target on shares of Equillium in a research note on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a research note on Friday, March 27th. Roth Mkm reiterated a “buy” rating and set a $12.00 price target on shares of Equillium in a research note on Thursday, May 28th. Finally, B. Riley Financial initiated coverage on shares of Equillium in a research note on Thursday, April 16th. They issued a “buy” rating and a $6.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Equillium currently has a consensus rating of “Moderate Buy” and an average price target of $7.57.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.